Chinese COVID-19 Vaccine Production Targets 2 Billion Doses Annually

Beijing-based Sinovac Biotech Ltd. announced that the third production line of CoronaVac®, its COVID-19 vaccine, was completed and put into commercial production. Including this new production line, Sinovac’s annual capacity of CoronaVac has reached 2 billion doses.

As of April 1, 2021, over 200 million doses of CoronaVac have been delivered to over 20 countries, including China.

In the capacity expansion process, Sinovac adhered to the most stringent requirements and did not sacrifice quality for speed and expansion. China’s National Medical Products Administration (NMPA) has inspected the new production line in compliance with quality specifications.

The facility and quality management system of CoronaVac has been inspected by China, Brazil, Indonesia, Chile, Singapore, and Saudi Arabia, as well as the World Health Organization. The large-scale production of hundreds of batches of COVID-19 vaccine proved that the vaccine production process is controllable and the quality is reliable.

Sinovac's press statement indicated it 'will continue to promote the production, supply, and various research studies of CoronaVac® to ensure quality and safety, strive to meet the pandemic prevention and control needs, and make positive contributions to the availability affordability of the COVID-19 vaccine on a global basis.'

Thus far, Sinovac’s COVID-19 vaccine received emergency use approval, or conditional marketing authorization, from over 30 countries.

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacturing, and commercialization of vaccines that protect against human infectious diseases.